These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Cellular delivery of siRNA and antisense oligonucleotides via receptor-mediated endocytosis. Ming X Expert Opin Drug Deliv; 2011 Apr; 8(4):435-49. PubMed ID: 21381985 [TBL] [Abstract][Full Text] [Related]
23. RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions. MacLeod AR; Crooke ST J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S43-S59. PubMed ID: 28921648 [TBL] [Abstract][Full Text] [Related]
24. Safety of antisense oligonucleotide and siRNA-based therapeutics. Chi X; Gatti P; Papoian T Drug Discov Today; 2017 May; 22(5):823-833. PubMed ID: 28159625 [TBL] [Abstract][Full Text] [Related]
25. Biological barriers to therapy with antisense and siRNA oligonucleotides. Juliano R; Bauman J; Kang H; Ming X Mol Pharm; 2009; 6(3):686-95. PubMed ID: 19397332 [TBL] [Abstract][Full Text] [Related]
26. Targeting murine alveolar macrophages by the intratracheal administration of locked nucleic acid containing antisense oligonucleotides. Uemura Y; Kobayashi K Drug Deliv; 2019 Dec; 26(1):803-811. PubMed ID: 31385541 [TBL] [Abstract][Full Text] [Related]
27. Knockdown of Z Mutant Alpha-1 Antitrypsin In Vivo Using Modified DNA Antisense Oligonucleotides. Aghajan M; Guo S; Monia BP Methods Mol Biol; 2017; 1639():127-138. PubMed ID: 28752452 [TBL] [Abstract][Full Text] [Related]
29. Silencing microRNA by interfering nanoparticles in mice. Su J; Baigude H; McCarroll J; Rana TM Nucleic Acids Res; 2011 Mar; 39(6):e38. PubMed ID: 21212128 [TBL] [Abstract][Full Text] [Related]
30. Genetics of Nonalcoholic Fatty Liver Disease: From Pathogenesis to Therapeutics. Sookoian S; Pirola CJ Semin Liver Dis; 2019 May; 39(2):124-140. PubMed ID: 30912099 [TBL] [Abstract][Full Text] [Related]
31. Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug. Debacker AJ; Voutila J; Catley M; Blakey D; Habib N Mol Ther; 2020 Aug; 28(8):1759-1771. PubMed ID: 32592692 [TBL] [Abstract][Full Text] [Related]
32. Drug delivery system of therapeutic oligonucleotides. Asami Y; Yoshioka K; Nishina K; Nagata T; Yokota T Drug Discov Ther; 2016; 10(5):256-262. PubMed ID: 27890899 [TBL] [Abstract][Full Text] [Related]
33. Overcoming the challenges of tissue delivery for oligonucleotide therapeutics. Gökirmak T; Nikan M; Wiechmann S; Prakash TP; Tanowitz M; Seth PP Trends Pharmacol Sci; 2021 Jul; 42(7):588-604. PubMed ID: 34020790 [TBL] [Abstract][Full Text] [Related]
34. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Juliano R; Alam MR; Dixit V; Kang H Nucleic Acids Res; 2008 Jul; 36(12):4158-71. PubMed ID: 18558618 [TBL] [Abstract][Full Text] [Related]
35. Achieving successful delivery of oligonucleotides--From physico-chemical characterization to in vivo evaluation. Scomparin A; Polyak D; Krivitsky A; Satchi-Fainaro R Biotechnol Adv; 2015 Nov; 33(6 Pt 3):1294-309. PubMed ID: 25916823 [TBL] [Abstract][Full Text] [Related]